It’s a reversal of fortunes for a Pfizer plant in Australia. The U.S. drugmaker has decided to close the facility and lay off nearly 90 workers after announcing expansion plans for the site a year ago.
Pfizer has announced it will close the plant in Adelaide by the end of 2021 as it again consolidates its manufacturing, ABC News in Australia reported. The plant currently has 89 workers.
“This has been a difficult decision, and was based on a number of factors including the existing capacity within Pfizer’s global manufacturing network and the efficiency of consolidating manufacturing to fewer locations,” the company said in a statement, the news site reported.
The drugmaker announced in March last year it would invest about $15.7 million (AU$21 million) to expand the capacity at the Adelaide plant that makes pegfilgrastim, the active ingredient for Amgen’s cancer drug Neulasta.
It is the second Pfizer plant in Australia to be slated for closure in recent years. The drugmaker in 2015 closed a plant in Sydney, laying off about 140 workers.
By Eric Palmer
Source: Fierce Pharma
The companies will explore opportunities to apply Flagship’s innovative bioplatforms – an ecosystem that currently comprises 41 companies – to scientific challenges in disease areas within cardiometabolic and rare diseases and initiate research programmes based on these.
BD is expanding its long-running partnership with the blood collection company Babson Diagnostics. The two companies have been working together since 2019 on a device that can gather small volumes of blood from the capillaries in the fingertip without requiring any specialized training, and beginning with a focus on supporting primary care in retail settings.
Wednesday, Australian biotech CSL said (PDF) the regulatory review of its $11.7 billion acquisition of Switzerland’s Vifor Pharma will take “a few more months,” suggesting it won’t be able to close the transaction by June 2022 as previously expected.
